Mutations in p53 cDNA sequence introduced by retroviral vector

Area of Science:

• Molecular Biology
• Cancer Genetics
• Gene Therapy

Background:

• Retroviral vectors are utilized in gene therapy, but their high mutation rates pose a challenge.
• The tumor suppressor gene p53 plays a critical role in preventing cancer.

Purpose of the Study:

• To investigate the mutation rates and spectra of p53 sequences transduced via retroviral vectors in a cancer gene therapy model.
• To assess the risk of cancer cells developing resistance to p53 gene therapy due to retroviral vector errors.

Main Methods:

• p53-deficient non-small cell lung cancer cells (H358) were treated with a retroviral vector carrying normal p53 cDNA.
• Analysis of p53 cDNA structure in resistant clones using PCR.
• Introduction of a retroviral vector with a non-functional p53 gene and Neo-resistant marker into H358 cells to determine mutation rates.

Main Results:

• Most transduced cells with functional p53 underwent apoptosis; however, resistant clones exhibited high mutation rates (88/102), including rearrangements, deletions, insertions, and base substitutions.
• Analysis using a non-functional p53 gene showed a low base substitution rate (1/95 clones), suggesting specific p53 mutations are not favored.
• These findings indicate that while the intrinsic mutation rate of p53 is not elevated, retroviral replication errors can lead to significant genetic alterations in cancer cells.

Conclusions:

• Retroviral vector-mediated gene therapy targeting p53 faces challenges due to potential mutations.
• Cancer cells can develop resistance to p53 gene therapy through mechanisms linked to retroviral replication errors.
• Careful consideration of retroviral vector fidelity is crucial for effective and safe gene therapy applications.